Metabolic Alterations in Posterior Fossa Malignancies
2026-08-11
Derek Dang’s dissertation examines posterior fossa malignancies through a metabolic framework that extends beyond the classical Warburg effect. Its central contribution is the emphasis on tumor-specific metabolic biology, while its available record also highlights the need to connect metabolic phenotypes with rigorous molecular and biochemical validation.
Anlotinib Hydrochloride Assay Guide
2026-08-10
A scenario-driven guide to using Anlotinib hydrochloride (SKU C8688) in viability, proliferation, migration, and angiogenesis assays. It connects receptor-level potency with practical controls, protocol optimization, data interpretation, and evidence-based product selection.
Tropifexor and the Next Frontier in FXR Translation
2026-08-09
Tropifexor (LJN452) offers a precise way to interrogate FXR biology across intestinal barrier, liver, and metabolic disease research. By connecting recent evidence on triacetin digestion with a disciplined FXR-focused workflow, translational teams can separate mechanistic opportunity from unsupported therapeutic assumptions.
EPZ5676: Mapping DOT1L Inhibition to Leukemia Biology
2026-08-08
EPZ5676 is a highly selective DOT1L inhibitor for connecting SAM-site target engagement with H3K79 methylation inhibition and MLL-fusion leukemia phenotypes. This guide adds a practical assay framework informed by a contrasting histone-demethylase study.
Mitoxantrone Targets the ERα DBD–LBD Interface
2026-08-07
Wang et al. identify mitoxantrone as a ligand for an allosteric interface between the estrogen receptor α DNA-binding and ligand-binding domains. The study shows that this interaction promotes receptor redistribution and proteasomal degradation, suppressing wild-type and endocrine therapy-resistant ERα activity in cellular and xenograft models.
3-Bromopyruvate and Cetuximab: Inducing Ferroptosis to Overc
2026-08-07
The highlighted study demonstrates that co-treatment with 3-bromopyruvate and cetuximab reverses resistance in colorectal cancer cells by inducing autophagy-dependent ferroptosis and apoptosis. Mechanistic insights reveal activation of FOXO3a pathways, suggesting a new therapeutic strategy for refractory CRC.
HyperScribe All in One mRNA Synthesis Kit Plus 1: Workflow &
2026-08-06
The HyperScribe All in One mRNA Synthesis Kit Plus 1 empowers researchers with a streamlined, high-yield protocol for ARCA-capped, immune-evasive mRNA—enabling advanced RNA vaccine development and functional genomics. With robust performance in polyadenylation and modified nucleotide incorporation, this kit excels in applications where stability, translation, and immune response modulation are critical.
XAV-939 in Direct Cardiac Reprogramming: A New Era for Wnt P
2026-08-06
Explore how XAV-939, a potent tankyrase inhibitor, enables advanced cardiac reprogramming and Wnt/β-catenin pathway modulation. This article uncovers unique translational insights and protocol guidance, setting it apart from prior research content.
PX-478 2HCl: Optimizing Hypoxia Pathway Research Workflows
2026-08-05
PX-478 2HCl empowers researchers to dissect hypoxia-driven signaling, radiosensitize tumor cells, and model ischemic responses with precision. This guide delivers workflow enhancements, troubleshooting strategies, and contextualizes PX-478’s role in translational cancer research.
UK-5099 (PF-1005023): Unlocking Mitochondrial Pyruvate Contr
2026-08-05
Discover how UK-5099 (PF-1005023) revolutionizes mitochondrial metabolism research, enabling precision in metabolic pathway interrogation for immunometabolic assays. This article uniquely explores the mechanistic and assay design implications of UK-5099, referencing the latest standardized whole-blood stimulation protocol.
BML-277: Chk2 Inhibitor Unlocks DNA Damage Response Assays
2026-08-04
BML-277 is a highly selective Chk2 inhibitor that empowers researchers to dissect DNA damage response pathways, probe radioprotection of T-cells, and explore posttranslational genome stability mechanisms. Its robust ATP-competitive inhibition and solubility profile make it ideal for advanced kinase assays and cellular studies targeting the Chk2–cGAS axis.
Resazurin Sodium Salt: Next-Gen Cytotoxicity Assessment in D
2026-08-04
Explore the advanced role of Resazurin sodium salt as a fluorogenic oxidation-reduction indicator for challenging cell models and cytotoxicity testing. This article delivers unique protocol insights, critical reference analysis, and practical guidance beyond standard viability assays.
Pharmacokinetics of CSBTA in MASH: Enzyme and Transporter In
2026-08-03
This study investigates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. By integrating transporter and enzyme profiling, it reveals mechanistic bases for dosing variability in MASLD/MASH research models.
Targeted Amikacin Sulfate Delivery: Transforming NTM Therapy
2026-08-03
This thought-leadership article explores the paradigm-shifting potential of targeted Amikacin Sulfate delivery for non-tuberculous mycobacterial (NTM) infections. Integrating mechanistic insights, experimental evidence, and translational strategy, it highlights how advances in intracellular drug uptake and dendritic cell–mediated delivery could overcome longstanding barriers in antibiotic therapy, reduce toxicity, and improve clinical outcomes. The article draws on reference studies and recent workflow innovations, positioning APExBIO's Amikacin Sulfate as a research-grade solution for next-generation infectious disease models.
Amikacin Sulfate: Advanced Workflows for Intracellular Targe
2026-08-02
Amikacin Sulfate empowers research on non-tuberculous mycobacterial infections with robust intracellular delivery and minimal toxicity. Discover optimized protocols, troubleshooting strategies, and cutting-edge insights for maximizing experimental success—leveraging APExBIO’s rigorously validated product.
461 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page